What is Zacks Research’s Estimate for APLS FY2024 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at Zacks Research reduced their FY2024 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 26th. Zacks Research analyst R. Department now anticipates that the company will earn ($1.78) per share for the year, down from their prior forecast of ($1.55). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.71) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.40) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.55) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue was up 78.3% compared to the same quarter last year. During the same period last year, the company posted ($1.17) earnings per share.

Other analysts have also issued research reports about the company. Scotiabank dropped their price objective on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target on the stock. The Goldman Sachs Group reduced their price objective on shares of Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. William Blair initiated coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They issued an “outperform” rating on the stock. Finally, Citigroup reduced their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.94.

Apellis Pharmaceuticals Trading Up 4.6 %

Shares of NASDAQ:APLS opened at $34.14 on Thursday. Apellis Pharmaceuticals has a 52-week low of $24.34 and a 52-week high of $73.80. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The company has a market capitalization of $4.25 billion, a P/E ratio of -16.82 and a beta of 0.87. The company has a 50-day simple moving average of $28.74 and a 200 day simple moving average of $35.41.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Braidwell LP raised its holdings in shares of Apellis Pharmaceuticals by 410.8% during the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after buying an additional 2,513,383 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Apellis Pharmaceuticals by 191.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after acquiring an additional 1,409,707 shares during the last quarter. Fiera Capital Corp raised its stake in Apellis Pharmaceuticals by 47.7% during the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after acquiring an additional 452,753 shares in the last quarter. Sphera Funds Management LTD. bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth about $6,226,000. Finally, AQR Capital Management LLC boosted its stake in shares of Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after purchasing an additional 190,420 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. This trade represents a 27.01 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.80% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).